COA Representatives Join Congressional Briefing on Personalized Medicine and the Future of Cancer Care Delivery and Payment

coapharm2017-09-14T17:11:41+00:00September 14, 2017|

It’s time to reform accessibility to prescription drugs

coapharm2017-09-13T13:07:06+00:00September 13, 2017|

Cancer drugs’ high prices not justified by cost of development, study contends

coapharm2017-09-13T13:00:44+00:00September 13, 2017|

Cancer immunotherapy proves itself in earlier-stage disease

coapharm2017-09-11T13:26:12+00:00September 11, 2017|

Clovis CEO deems new Rubraca data ‘better’ than its PARP rivals. Is it enough?

coapharm2017-09-08T14:30:37+00:00September 8, 2017|

CancerCare to Support Cancer Patients Affected by Hurricane Harvey

coapharm2017-09-08T14:27:47+00:00September 8, 2017|

Pharma strikes back at Nevada pricing law with lawsuit alleging it’s ‘unprecedented and unconstitutional’

coapharm2017-09-07T19:52:08+00:00September 7, 2017|

After Keytruda deaths, FDA hits pause on Bristol-Myers Squibb’s Opdivo myeloma trials

coapharm2017-09-07T19:49:58+00:00September 7, 2017|

When a Company Is Making Money From the Opioid Crisis

coapharm2017-09-07T19:41:36+00:00September 7, 2017|

Proposed Changes to 340B May Curb Hospital Abuses

coapharm2017-09-05T19:28:22+00:00September 5, 2017|